(Natural News)—On Jan. 12, Congresswoman Marjorie Taylor Greene held, on behalf of the House Select Subcommittee on the Coronavirus Pandemic, a hearing on adverse events, including increasing rates of myocarditis, pericarditis and blood clots post-Wuhan coronavirus (COVID-19) vaccination.
Drs. Peter McCullough, Ryan Cole and Kirk Milhoan, who were the most outspoken medical professionals on the inefficacy and unsafety of mRNA inoculation, presented their testimonies that day. Over the past few years, they got canceled by insurance companies, got fired from their jobs and faced massive public scrutiny and the danger of losing their licenses.
At one point in the testimonials, Greene raised a concern apart from the given and proven fact that the “shots” contained foreign spike proteins that harm the body systems and create blood clots. The three doctors have cited several studies proving these are true but lamented how President Joe Biden’s government agencies ignored them. Another point is that the Big Pharma companies seem to have manufactured medications and vaccines that would “cure” the adverse reactions brought about by the SARS-CoV-2 vaccine.
Green even quoted the pharmaceutical companies to “Sell the disease and then sell the cure. And their friends in Congress, in turn, force Americans to pay for it. This is how Washington works in many cases.” “Is it fair to say then that these vaccine manufacturers created these vaccines with synthetic mRNA that has created heart disease, strokes, neurological problems and everything that you’ve talked about, do these same manufacturers sell the cures for the diseases that they’re creating?” she asked.
Cole, a board-certified anatomic and clinical pathologist, did not answer directly but said he finds it ironic that major drug manufacturer Pfizer just spent $40 billion on a cancer treatment company. According to reports, since the commencement of COVID-19 vaccines, there has been an unprecedented rise in the deaths of young people between 2021 and 2022 from rapidly metastasizing and terminal cancers, according to data from the U.K.’s Office for National Statistics. Also, Pfizer’s mRNA vaccine was found to be contaminated with cancer-causing DNA fragments.
McCollough, an internist and cardiologist, chimed in saying that following the roll-out of the mRNA vaccines, “I’ve never prescribed so many blood thinners in my career. This is extraordinary. All day long, I’m confronted with blood clots of different scenarios,” he said. Elsewhere in the meeting, the early treatment proponent for coronavirus also revealed how the prices are skyrocketing for medical procedures. Recently, he has been ordering more and more cardiac magnetic resonance images (MRIs) and electrocardiograms (ECG or EKG) and seeing recurrent visits to the emergency room, especially those who are military servicemen.
Medical government arms earned from Big Pharma
Halfway into the two-hour hearing, the floor was turned over to Congressman Andy Biggs, who named some of the 1246 unique medical conditions that arose since the inoculation drives have been mandated. He reminded all attendees that before Prizer was mandated by a Freedom of Information Act (FOIA) request to release the results of their clinical trials, the pharma company intended to keep these side effects a secret for 75 years.
He asked the doctors what drove the establishment to basically ignore these. “Is this because of money? Are there kickbacks available to government officials?” Biggs asked.
Cole answered this first by saying, “If we go back historically, unfortunately, a lot of laws that have been passed over time built up this machine that’s almost unstoppable,” he said citing the Public Readiness and Emergency Preparedness Act (Prep Act) and the Bayh-Dole Act, formerly known as the Patent and Trademark Act Amendments, which allowed universities to make billions of dollars off their patents. “Does the government work for the people or does the government work for industry? That’s the big question and you know there’s so much lobby money,” he pointed out. “The [Food and Drug Administration] FDA is captured by pharmaceutical companies in terms of what percentage of their budget they get from pharma for drug approval and fast-tracking.”
He also mentioned the CDC Foundation, which also makes billions of dollars off vaccine patents. It now holds the patents for up to 58 vaccines. Another government agency is the National Institutes of Health (NIH), which has officials who make $150,000 a year for the rest of their lives if they have a patent on a drug that goes to market.
“There are intertwining corrupted and financial interests, certainly. When we as a nation value money over our freedom and when we value our own self-interest over having a constitution that matters to each one of us, then we’re on the wrong track,” Cole emphasized.
Watch the full unedited coverage of the Congressional hearing on the injuries caused by COVID-19 vaccines below.
Visit VaccineInjuryNews.com to read more stories on the adverse side effects of COVID-19 shots.
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.